Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Rises By 132.4%

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 92,500 shares, an increase of 132.4% from the January 15th total of 39,800 shares. Based on an average daily volume of 497,000 shares, the short-interest ratio is currently 0.2 days.

Astellas Pharma Stock Performance

Shares of ALPMY stock opened at $9.73 on Friday. The company has a market cap of $17.61 billion, a P/E ratio of -44.23 and a beta of 0.34. The firm has a fifty day moving average price of $9.71 and a 200 day moving average price of $10.90. The company has a current ratio of 1.10, a quick ratio of 0.86 and a debt-to-equity ratio of 0.41. Astellas Pharma has a 12 month low of $9.05 and a 12 month high of $13.14.

Astellas Pharma (OTCMKTS:ALPMY) last released its quarterly earnings data on Tuesday, February 4th. The company reported $0.30 earnings per share (EPS) for the quarter. Astellas Pharma had a positive return on equity of 13.48% and a negative net margin of 3.10%. Sell-side analysts predict that Astellas Pharma will post 0.58 earnings per share for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.